Table 3.
Assessment of bleb morphologies, outcomes, and complications in the HealaFlow® and MMC group at 12 months
| Variables | Group | P | ||
|---|---|---|---|---|
| HealaFlow® (n=28) (%) | MMC (n=28) (%) | |||
| Outcome | Complete success | 25 (89.29%) | 25 (89.29%) | 1MC |
| Qualified success | 3 (10.71%) | 3 (10.71%) | ||
| Complications | Nil | 25 (89.29%) | 25 (89.29%) | 1MC |
| Hyphaema | 2 (7.14%) | 2 (7.14%) | ||
| Subconjunctival hemorrhage under bleb | 1 (3.57%) | 1 (3.57%) | ||
| Central bleb area | 25% | 22 (78.57%) | 18 (64.29%) | 0.2367 |
| 50% | 6 (21.43%) | 10 (35.71%) | ||
| Peripheral bleb area | 0% | 8 (28.57%) | 11 (39.29%) | 0.3972 |
| 25% | 20 (71.43%) | 17 (60.71%) | ||
| Bleb height | Low | 11 (39.29%) | 4 (14.29%) | 0.1068 |
| Flat | 4 (14.29%) | 6 (21.43%) | ||
| Moderately elevated | 13 (46.43%) | 18 (64.29%) | ||
| Bleb Vascularity | Normal | 13 (46.43%) | 13 (46.43%) | 0.7575 |
| Mild | 5 (17.86%) | 7 (25%) | ||
| Avascular | 10 (35.71%) | 8 (28.57%) | ||
MC: Monte-Carlo’s simulation used to obtain P